Evidence map›Paper›PMID 31149538›Full record

ArticleInternational cancer conference journal2019

Multidisciplinary treatment for locally advanced breast cancer with internal mammary lymph node metastasis in an elderly patient.

Haruko Takuwa, Wakako Tsuji, Yoshihiro Yamamoto, Chikako Yamauchi, Fumiaki Yotsumoto

Erratum issuedOpen access · bronzeAbstract readCase Reports
In one paragraph

Article in International cancer conference journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.0field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Haruko TakuwaDepartment of Breast Surgery, Shiga General Hospital, 5-4-30, Moriyama-shi, Moriyama, Shiga 524-8524 Japan.ORCID 0000-0002-2897-8700
Wakako TsujiDepartment of Breast Surgery, Shiga General Hospital, 5-4-30, Moriyama-shi, Moriyama, Shiga 524-8524 Japan.
Yoshihiro YamamotoDepartment of Pathology, Shiga General Hospital, Moriyama, Shiga Japan.
Chikako YamauchiDepartment of Radiation Oncology, Shiga General Hospital, Moriyama, Shiga Japan.
Fumiaki YotsumotoDepartment of Breast Surgery, Shiga General Hospital, 5-4-30, Moriyama-shi, Moriyama, Shiga 524-8524 Japan.
Shiga Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Internal mammary lymph node (IMLN) metastasis is one of the important prognostic indicators in breast cancer. However, the management for IMLN metastasis is not established. The dissection for IMLN metastasis is not recommended in the National Comprehensive Cancer Network guidelines version3. 2015. Furthermore, radiotherapy including IMLN region and biopsy have attendant risks and hence should be performed with caution. Here, we describe our experience of multidisciplinary treatment for locally advanced breast cancer with IMLN metastasis in an elderly patient. Core-needle biopsy of the breast tumor histologically diagnosed the tumor as estrogen receptor positive, progesterone receptor positive, human epidermal growth factor receptor-2 negative, and high Ki-67 labeling index. IMLN swelling was detected by ultrasonography and breast cancer metastasis was diagnosed by fine-needle aspiration cytology. The patient underwent mastectomy and axillary lymph node dissection, followed by postmastectomy radiation therapy. Systemic therapy using tegafur plus uracil (UFT®; Taiho Pharmaceutical Co., Ltd, Tokyo, Japan) and letrozole was beneficial treatment for disease control.

Indexed as

Breast cancerInternal mammary lymph node metastasisMultidisciplinary therapy

Identifiers

PMID31149538
PMCPMC6498371
OpenAlexW2892117387

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.